BioWorld

Aug. 14, 2002

Dendreon's Trp-p8 Gene Platform Garners $110M Genentech Deal

Dendreon Corp. could gain more than $110 million in a deal with Genentech Inc. to develop monoclonal antibodies, small molecules and other products from Dendreon's preclinical Trp-p8 gene platform. (BioWorld Today) Read More

Nobex Raises Two Year's Cash Through $35M Private Placement

GenVec's Flagship AntiCancer Drug, TNFerade, Performs Well In Both Preclinical, Clinical Trials

$37M Addition Brings Archemix Series A Financing To $51.75M

Other News To Note

CollaGenex Testing Periostat In Phase III Against Rosacea

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...